 Provider News MaineFebruary 2024 Provider NewsletterAdministrative | Anthem Blue Cross and Blue Shield | Commercial | February 1, 2024 Notice of material change/amendment to contract Notices of material changes/amendments to contract — February 2024Notices of material changes/amendments to contract may apply for new or updated reimbursement policies, medical policies, or prior authorization requirements. In this issue, please reference the following articles: - Medical Policy and Clinical Guideline updates
- Clinical Criteria updates for specialty pharmacy
- New reimbursement policy: Modifier Usage – Facility update
- MCG care guidelines 27th edition update
- Claims Match Enhancement for Carelon Medical Benefits Management, Inc. Genetic Testing
- Carelon Medical Benefits Management, Inc. genetic testing code updates
- Specialty pharmacy updates — February 2024
Carelon Medical Benefits Management, Inc. is an independent company providing utilization management services on behalf of the health plan. Anthem Blue Cross and Blue Shield is the trade name of Anthem Health Plans of Maine, Inc. Independent licensee of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MEBCBS-CM-048816-24 Please review your online provider directory information on a regular basis to ensure it is correct. Access your online provider directory information by visiting anthem.com, then at the top of the webpage, select Find Care. Submit updates and corrections to your directory information by following the instructions on the Provider Maintenance Form online. Update options include: - add/change an address location
- name change
- phone/fax number change
- provider leaving a group or a single location
- closing a practice location
The Consolidated Appropriations Act (CAA) implemented in 2021 contains a provision that requires online provider directory information be reviewed and updated as needed at least every 90 days. By reviewing your information regularly, you help us ensure your online provider directory information is current. We share a health vision with our care providers that means real change for consumers. Anthem Blue Cross and Blue Shield is the trade name of Anthem Health Plans of Maine, Inc. Independent licensee of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CM-049338-24 To help inform referrals and placements, we are asking all home health agencies to complete this survey, which will allow us to have the most up-to-date information about your facility and allow us to provide the best possible service to you and to our members. With your help, we can continually build towards a future of shared success. Please complete the survey here. It should only take about 10 minutes of your time. Anthem Blue Cross and Blue Shield is the trade name of Anthem Health Plans of Maine, Inc. Independent licensee of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MEBCBS-CM-048850-23-CPN45030 This article was published in error and retracted on February 21, 2024. Please access your state's updated version: Colorado, Connecticut, Georgia, Indiana, Kentucy, Maine, Missouri, Nevada, New Hampshire, New York, Ohio, Virginia, Wisconsin You may submit all your prior authorizations in one application on Availity.com.
You may already be submitting your prior authorizations through the Availity multi-payer Authorization application — taking advantage of the time savings and speed to care through digital authorization submissions. Beginning in March, you can submit both your physical health and behavioral health prior authorizations through one Authorization application on Availity.com.
You can still access the Interactive Care Reviewer (ICR) to review cases that were submitted through that application. You will also continue to use ICR to submit an appeal or authorization for medical specialty Rx.
Using the Availity Authorization application to submit your behavioral health prior authorizations will not be much different from the process you follow today. You may enjoy more intuitive screens or learn sooner if an authorization is required — but the digital submission process is still the very best way to submit your prior authorization and the fastest way to care for our members.
Training is available
If you aren’t already familiar with Availity Authorization, training is available. Select Availity Authorization Training to enroll for an upcoming live webcast or to access an on-demand recording.
Now, give it a try!
Accessing the Availity for authorization is easy. Ask your organization’s Availity administrator to ensure you have the Authorization role assignment. Without the role assignment, you will not be able to access the Authorization application. Then, log on to Availity.com to access the app through the Patient Registration tab by selecting Authorizations and Referrals.
Anthem Blue Cross and Blue Shield is the trade name of Anthem Health Plans of Maine, Inc. Independent licensee of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CM-049149-23-CPN48082 Beginning in February 2024, we will notify you through your Attachments Dashboard when we need medical records, itemized bills, or other documents required to process our member’s claims. When your organization registered to use the Medical Attachments application through Availity Essentials, you also registered to receive digital notifications through that application. This makes it possible for us to notify you digitally when we need documents to process your claim. Digital Request for Additional Information (Digital RFAI) is 50% faster than returning documentation and itemized bills any other way — making it the most efficient way to receive and return information.* Digital RFAI also eliminates the guess work associated with claim documentation by sending you a notification that tells you exactly what is needed. Notifications arrive daily on your Attachments Dashboard on Availity.com so there is no need to key-in claims information to attach documents. Be ready — Take an on-demand or live learning sessionIn collaboration with Availity, we’ve developed a precheck program for your organization’s Availity administrators to ensure your Medical Attachment registration is complete and that you are prepared for Digital RFAI. It is very important that your Availity administrators use this link to register to view the live training on-demand. For associates who are responsible for sending attachments, we’ve developed an enhanced training session that walks through the Attachments Dashboard and many of the unique features that make it most efficient. Availity users with the Medical Attachments and Claims Status role assignment should use this link to register to view the live training on-demand. Resources availableFor additional resources, contact your provider relationship management representative. * Internal post-launch phase one survey. June 2022. Anthem Blue Cross and Blue Shield is the trade name of Anthem Health Plans of Maine, Inc. Independent licensee of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MEAMH-CR-049413-23-CPN48759 Policy Updates | Anthem Blue Cross and Blue Shield | Commercial | February 1, 2024 Notice of material change/amendment to contract MCG care guidelines 27th edition updateEffective June 1, 2024, Anthem will transition from CG-BEH-02 (Adaptive Behavioral Treatment) and MCG W0153 (Behavioral Health Care Applied Behavioral Analysis), to MCG B-806-T Behavioral Health Care Applied Behavioral Analysis (Original MCG Guideline), for medical necessity/clinical appropriateness reviews. If you have questions, please contact the provider service number on the back of the member's ID card. Anthem Blue Cross and Blue Shield is the trade name of Anthem Health Plans of Maine, Inc. Independent licensee of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CM-047274-23 Policy Updates | Anthem Blue Cross and Blue Shield | Medicare Advantage / AMH Health, LLC | Medicare Advantage | January 18, 2024 Clinical Criteria updates — September 2023SummaryOn September 21, 2023, and October 4, 2023, the Pharmacy and Therapeutic (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for AMH Health. These policies were developed, revised, or reviewed to support clinical coding edits. Visit Clinical Criteria to search for specific policies. For questions or additional information, use this email. Please see the explanation/definition for each category of Clinical Criteria below: - New: newly published criteria
- Revised: addition or removal of medical necessity requirements, new document number
- Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive
Please share this notice with other providers in your practice and office staff. Please note: - The Clinical Criteria listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services.
- This notice is meant to inform the provider of new or revised criteria that has been adopted by AMH Health only. It does not include details regarding any authorization requirements. Authorization rules are communicated via a separate notice.
Effective date | Clinical Criteria number | Clinical Criteria title | New or revised | February 19, 2024 | *CC-0248 | Elrexfio (elranatamab-bcmm) | New | February 19, 2024 | *CC-0249 | Talvey (talquetamab-tgvs) | New | February 19, 2024 | *CC-0250 | Veopoz (pozelimab-bbfg) | New | February 19, 2024 | *CC-0251 | Pompe Disease | New | February 19, 2024 | *CC-0018 | Pompe Disease | Revised | February 19, 2024 | *CC-0021 | Fabrazyme (agalsidase beta) | Revised | February 19, 2024 | *CC-0046 | Zinplava (bezlotoxumab) | Revised | February 19, 2024 | CC-0182 | Iron Agents | Revised | February 19, 2024 | *CC-0068 | Growth Hormones | Revised | February 19, 2024 | CC-0156 | Reblozyl (luspatercept) | Revised | February 19, 2024 | *CC-0233 | Rebyota (fecal microbiota, live – jslm) | Revised | February 19, 2024 | *CC-0020 | Natalizumab Agents (Tysabri, Tyruko) | Revised | February 19, 2024 | CC-0064 | Interleukin-1 Inhibitors | Revised | February 19, 2024 | CC-0026 | Testosterone Injectable | Revised | February 19, 2024 | *CC-0247 | Beyfortus (nirsevimab) | Revised |
Anthem Blue Cross and Blue Shield is the trade name of Anthem Health Plans of Maine, Inc. Independent licensee of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MEAMH-CR-047339-23-CPN47070 Medical Policy & Clinical Guidelines | Anthem Blue Cross and Blue Shield | Commercial | February 1, 2024 Notice of material change/amendment to contract Medical Policy and Clinical Guideline updatesThe following new Medical Policies were endorsed at the November 9, 2023, Medical Policy & Technology Assessment Committee (MPTAC) meeting. This, and all Anthem’s Medical Policies and Clinical Guidelines, are available at anthem.com. Select For Providers. Under the Provider Resources heading, select Policies, Guidelines & Manuals. Select your state. Then, select View Medical Policies & Clinical UM Guidelines. To view Medical Policies and Clinical Utilization Management Guidelines applicable to members enrolled in the Blue Cross and Blue Shield Service Benefit Plan (commonly referred to as the Federal Employee Program® [FEP]), visit fepblue.org > Policies & Guidelines. Medical Policy updatesNew Medical Policy effective May 1, 2024 The following policy is new: - RAD.00068 Myocardial Strain Imaging*
Revised Medical Policies effective May 1, 2024 The policies below were revised and might result in services that were previously covered but may now be found to be either not medically necessary and/or investigational: - MED.00120 Gene Therapy for Ocular Conditions*
- SURG.00026 Deep Brain, Cortical, and Cerebellar Stimulation*
- SURG.00097 Scoliosis Surgery*
- SURG.00142 Genicular Procedures for Knee Pain*
* The applicable policy is attached to this article in PDF format. Anthem Blue Cross and Blue Shield is the trade name of Anthem Health Plans of Maine, Inc. Independent licensee of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MEBCBS-CM-048580-23 ATTACHMENTS (available on web): SURG.00097_Pub 12-28-2023 (pdf - 0.28mb) SURG.00026_Pub 12-28-2023 (pdf - 0.5mb) MED.00120_Pub 12-28-2023 (pdf - 0.25mb) RAD.00068_Pub 01-03-2024 (pdf - 0.22mb) SURG.00142_Pub 01-03-2024 (pdf - 0.24mb) Medical Policy & Clinical Guidelines | Anthem Blue Cross and Blue Shield | Commercial | January 24, 2024 Notice of material change/amendment to contract Carelon Medical Benefits Management, Inc. genetic testing code updatesEffective for dates of service on and after May 1, 2024, the following codes will require prior authorization through Carelon Medical Benefits Management, Inc. CPT® code | Description | 0239U | Targeted genomic sequence analysis panel, solid organ neoplasm, cell-free DNA, analysis of 311 or more genes, interrogation for sequence variants, including substitutions, insertions, deletions, select rearrangements, and copy number variations | 0306U | Targeted genomic sequence analysis panel, solid organ neoplasm, cell-free DNA, analysis of 311 or more genes, interrogation for sequence variants, including substitutions, insertions, deletions, select rearrangements, and copy number variations | 0307U | Oncology (minimal residual disease [MRD]), next-generation targeted sequencing analysis, cell-free DNA, initial (baseline) assessment to determine a patient specific panel for | 0356U | Oncology (liver), surveillance for hepatocellular carcinoma (HCC) in high-risk patients, analysis of methylation patterns on circulating cell-free DNA (cfDNA) plus measurement | 0368U | Oncology (colorectal cancer), evaluation for mutations of APC, BRAF, CTNNB1, KRAS, NRAS, PIK3CA, SMAD4, and TP53, and methylation markers (MYO1G, KCNQ5, C9ORF50, FLI1, CLIP4, ZNF132 and TWIST1), multiplex quantitative polymerase chain reaction (qPCR), circulating cell-free DNA (cfDNA), plasma, report of risk score for advanced adenoma or colorectal cancer | 0326U | Targeted genomic sequence analysis panel, solid organ neoplasm, cell-free circulating DNA analysis of 83 or more genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden |
As a reminder, ordering and servicing providers may submit prior authorization requests to Carelon Medical Benefits Management in one of several ways: - Access the ProviderPortalSM directly at providerportal.com:
- Online access is available 24/7 to process orders in real-time and is the fastest and most convenient way to request authorization.
- Access via Availity.com.
If you have questions related to guidelines, please contact Carelon via email at MedicalBenefitsManagement.guidelines@Carelon.com. Additionally, you may access and download a copy of the current and upcoming guidelines here. With your help, we can continually build towards a future of shared success. Carelon Medical Benefits Management, Inc. is an independent company providing utilization management services on behalf of the health plan. Anthem Blue Cross and Blue Shield is the trade name of Anthem Health Plans of Maine, Inc. Independent licensee of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CM-048270-23-CPN48141 Prior Authorization | Anthem Blue Cross and Blue Shield | Commercial | February 1, 2024 Notice of material change/amendment to contract Claims Match Enhancement for Carelon Medical Benefits Management, Inc. Genetic TestingAs part of our ongoing quality improvement efforts, we will be implementing a new Genetic Testing (GT) claim to authorization match enhancement that will ensure GT panels billed have a corresponding authorization. This enhanced match logic will be effective by May 1, 2024. Labs that bill panels with codes in excess of what has been authorized may receive a full claim denial. The goal of this enhanced match logic is to ensure tests performed are authorized and meet medical necessity requirements. Carelon Medical Benefits Management, Inc. is an independent company providing utilization management services on behalf of the health plan. Anthem Blue Cross and Blue Shield is the trade name of Anthem Health Plans of Maine, Inc. Independent licensee of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CM-047632-23-CPN47301 UPDATE: This article was originally published as being effective March 1, 2024. The effective date has been delayed to May 1, 2024. Effective May 1, 2024, prior authorization (PA) requirements will change for the following code(s). The medical code(s) listed below will require PA by AMH Health, LLC for Medicare members. Federal and state law, as well as state contract language and Centers for Medicare & Medicaid Services guidelines, including definitions and specific contract provisions/exclusions take precedence over these precertification rules and must be considered first when determining coverage. Non-compliance with new requirements may result in denied claims. Prior authorization requirements will be added for the following code(s): Code | Description | 0738T | Treatment planning for magnetic field induction ablation of malignant prostate tissue, using data from previously performed magnetic resonance imaging (MRI) examination | 0739T | Ablation of malignant prostate tissue by magnetic field induction, including all intraprocedural, transperineal needle/catheter placement for nanoparticle installation and int |
Not all PA requirements are listed here. Detailed PA requirements are available to providers on anthem.com/medicareprovider on the Resources tab or for contracted providers by accessing Availity.com. Providers may also call the number on the back of their patient’s member ID card .for assistance with PA requirements. UM AROW #: A2023M0443 Plans offered by AMH Health, LLC., a joint venture between MaineHealth and Anthem Partnership Holding Company, LLC. AMH Health is an independent licensee of the Blue Cross Blue Shield Association. MEAMH-CR-044237-23-CPN43832, CPN-CRMMP-049296-24 UPDATE: This article was originally published as being effective March 1, 2024. The effective date has been delayed to May 1, 2024. Effective May 1, 2024, prior authorization (PA) requirements will change for the following code(s). The medical code(s) listed below will require PA by AMH Health, LLC for Medicare members. Federal and state law, as well as state contract language and Centers for Medicare & Medicaid Services guidelines, including definitions and specific contract provisions/exclusions take precedence over these precertification rules and must be considered first when determining coverage. Non-compliance with new requirements may result in denied claims. Prior authorization requirements will be added for the following code(s): Code | Description | Q4272 | Esano a, per square centimeter | Q4273 | Esano aaa, per square centimeter | Q4274 | Esano ac, per square centimeter | Q4275 | Esano aca, per square centimeter | Q4276 | Orion, per square centimeter | Q4277 | Woundplus membrane or e-graft, per square centimeter | Q4278 | Epieffect, per square centimeter | Q4280 | Xcell amnio matrix, per square centimeter | Q4281 | Barrera sl or barrera dl, per square centimeter | Q4282 | Cygnus dual, per square centimeter | Q4283 | Biovance tri-layer or biovance 3l, per square centimeter | Q4284 | Dermabind sl, per square centimeter |
Not all PA requirements are listed here. Detailed PA requirements are available to providers on anthem.com/medicareprovider on the Resources tab or for contracted providers by accessing Availity.com. Providers may also call the number on the back of their patient’s member ID card .for assistance with PA requirements. UM AROW #: A2023M0417 Plans offered by AMH Health, LLC., a joint venture between MaineHealth and Anthem Partnership Holding Company, LLC. AMH Health is an independent licensee of the Blue Cross Blue Shield Association. MEAMH-CR-044200-23-CPN43849, CPN-CRMMP-049296-24 UPDATE: This article was originally published as being effective March 1, 2024. The effective date has been delayed to May 1, 2024. Effective May 1, 2024, prior authorization (PA) requirements will change for the following code(s). The medical code(s) listed below will require PA for AMH Health, LLC members. Federal and state law, as well as state contract language and Centers for Medicare & Medicaid Services guidelines, including definitions and specific contract provisions/exclusions take precedence over these precertification rules and must be considered first when determining coverage. Non-compliance with new requirements may result in denied claims. Prior authorization requirements will be added for the following code(s): Code | Description | E0761 | Non-Thermal Pulsed High Frequency Radiowaves, High Peak Power Electrom |
Not all PA requirements are listed here. Detailed PA requirements are available to providers on anthem.com/medicareprovider on the Resources tab or for contracted providers by accessing Availity.com. Providers may also call the number on the back of their patient’s member ID card for Provider Services. UM AROW #: A2023M0415 Plans offered by AMH Health, LLC., a joint venture between MaineHealth and Anthem Partnership Holding Company, LLC. AMH Health is an independent licensee of the Blue Cross Blue Shield Association. MEAMH-CR-044186-23-CPN43845, CPN-CRMMP-049296-24 Reimbursement Policies | Anthem Blue Cross and Blue Shield | Commercial | February 1, 2024 Notice of material change/amendment to contract New reimbursement policy: Modifier Usage — FacilityBeginning with dates of service on or after May 1, 2024, Anthem will implement a new reimbursement policy titled Modifier Usage — Facility based on the code-set combinations submitted with the correct modifiers. This reimbursement policy identifies the following three different types of facility modifiers: - Reimbursement modifiers affect payment and denote circumstances when an increase or reduction is appropriate for the service provided.
- Informational modifiers impacting reimbursement determine if the service provided will be reimbursed or denied.
- Informational modifiers not impacting reimbursement are used for documentation purposes.
The Related Coding section of the policy includes a Facility Modifier code list which identifies the modifier, the modifier description, and any related reimbursement policies. The Facility Modifier code list also includes six modifiers that do not have associated reimbursement policies. These modifiers indicate a reduced service or different equipment was used for the service. These modifiers will result in a reduction when billed on a facility claim. For specific policy details, visit the reimbursement policy page at anthem.com. Anthem Blue Cross and Blue Shield is the trade name of Anthem Health Plans of Maine, Inc. Independent licensee of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CM-047155-23-SRS47155 ATTACHMENTS (available on web): Modifier Usage Facility BCBS CM 11082023 ME (pdf - 0.13mb) Pharmacy | Anthem Blue Cross and Blue Shield | Commercial | January 24, 2024 Notice of material change/amendment to contract Specialty pharmacy updates — February 2024This article was updated on July 23, 2024 to correct the Clinical Criteria for Spravato (esketamine) from CC-0066 to CC-0086. Specialty pharmacy updates for Anthem are listed belowPrior authorization clinical review of non-oncology use of specialty pharmacy drugs is managed by Anthem’s Medical Specialty Drug Review team. Review of specialty pharmacy drugs for oncology use is managed by Carelon Medical Benefits Management, Inc., a separate company. Important to note: Currently, your patients may be receiving these medications without prior authorization. As of the effective date below, you may be required to request prior authorization review for your patients’ continued use of these medications. Inclusion of National Drug Code (NDC) code on your claim will help expedite claim processing of drugs billed with a Not Otherwise Classified (NOC) code. Prior authorization updatesUpdate: In the May 2023 edition of Provider News, we announced prior authorization for Adstiladrin will be effective August 2023. Review of Adstiladrin is managed by Carelon Medical Benefits Management. Effective for dates of service on and after May 1, 2024, the following specialty pharmacy codes from current or new Clinical Criteria documents will be included in our prior authorization review process. Access our Clinical Criteria to view the complete information for these prior authorization updates. Clinical Criteria | Drug | HCPCS or CPT® code(s) | CC-0252 | Adzynma (ADAMTS13, recombinant-krhn) | C9399 | CC-0253* | Aphexda (motixafortide) | J3490, J3590, J9999 | CC-0042 | Bimzelx (bimekizumab-bkzx) | J3490 | CC-0032 | Daxxify (daxibotulinumtoxinA-lanm) | C9160 | CC-0050 | Omvoh (mirikizumab-mrkz) | J3590 | CC-0066* | Tofidence (tocilizumab-bavi) | J3490, J3590 | CC-0254 | Zilbysq (zilucoplan) | J3490 | CC-0062 | Zymfentra (infliximab-dyyb) | J3590 |
* Oncology use is managed by Carelon Medical Benefits Management. Note: Prior authorization requests for certain medications may require additional documentation to determine medical necessity. Quantity limit updatesEffective for dates of service on and after May 1, 2024, the following specialty pharmacy codes from current or new Clinical Criteria documents will be included in our quantity limit review process. Access our Clinical Criteria to view the complete information for these quantity limit updates. Clinical Criteria | Drug | HCPCS or CPT code(s) | CC-0042 | Bimzelx (bimekizumab-bkzx) | J3490 | CC-0032 | Daxxify (daxibotulinumtoxinA-lanm) | C9160 | CC-0050 | Omvoh (mirikizumab-mrkz) | J3590 | CC-0066 | Tofidence (tocilizumab-bavi) | J3490, J3590 | CC-0254 | Zilbysq (zilucoplan) | J3490 | CC-0062 | Zymfentra (infliximab-dyyb) | J3590 | CC-0086 | Spravato (esketamine) | G2082, G2083, S0013 |
Through our efforts, we are committed to reducing administrative burden and ensuring timely payments because we value you, our care provider partners. Carelon Medical Benefits Management, Inc. is an independent company providing utilization management services on behalf of the health plan. Anthem Blue Cross and Blue Shield is the trade name of Anthem Health Plans of Maine, Inc. Independent licensee of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CM-048938-24-CPN48884, MEBCBS-CM-060982-24 ATTACHMENTS (available on web): Adzynma CC-0252 (pdf - 0.13mb) Aphexda CC-0253 (pdf - 0.12mb) Bimzelx CC-0042 (pdf - 0.26mb) Daxxify CC-0032 (pdf - 0.25mb) Monoclonal Antibodies to Interleukin-6 CC-0066 (pdf - 0.2mb) Omvoh CC-0050 (pdf - 0.3mb) Zilbrysq CC-0254 (pdf - 0.15mb) Zymfentra CC-0062 (pdf - 0.47mb) Pharmacy | Anthem Blue Cross and Blue Shield | Commercial | February 1, 2024 Notice of material change/amendment to contract Clinical Criteria updates for specialty pharmacyThe following Clinical Criteria documents were endorsed at the November 17, 2023, Clinical Criteria meeting. Visit our website to access the Clinical Criteria information. New Clinical Criteria effective May 1, 2024The following Clinical Criteria are new: - CC-0253 Aphexda (motixafortide)*
- CC-0254 Zilbysq (zilucoplan)*
Revised Clinical Criteria effective May 1, 2024The following Clinical Criteria were revised and might result in services that were previously covered but may now be found to be not medically necessary: - CC-0002 Colony Stimulating Factor Agents*
- CC-0009 Lemtrada (alemtuzumab) for the Treatment of Multiple Sclerosis*
- CC-0011 Ocrevus (ocrelizumab)*
- CC-0014 Beta Interferons and Glatiramer Acetate for Treatment of Multiple Sclerosis*
- CC-0020 Natalizumab Agents (Tysabri, Tyruko)*
- CC-0032 Botulinum Toxin*
- CC-0041 Complement Inhibitors*
- CC-0042 Monoclonal Antibodies to Interleukin-17*
- CC-0050 Monoclonal Antibodies to Interleukin-23*
- CC-0062 Tumor Necrosis Factor Antagonists*
- CC-0063 Ustekinumab Agents (Stelara, Wezlana)*
- CC-0064 Interleukin-1 Inhibitors*
- CC-0065 Agents for Hemophilia A and von Willebrand Disease*
- CC-0066 Monoclonal Antibodies to Interleukin-6*
- CC-0068 Growth Hormone*
- CC-0071 Entyvio (vedolizumab)*
- CC-0078 Orencia (abatacept)*
- CC-0086 Spravato (esketamine) Nasal Spray*
- CC-0170 Uplizna (inebilizumab-cdon)*
- CC-0173 Enspryng (satralizumab-mwge)*
- CC-0174 Kesimpta (ofatumumab)*
- CC-0182 Iron Agents*
- CC-0199 Empaveli (pegcetacoplan)*
- CC-0226 Elahere (mirvetuximab)*
* The applicable policy is attached to this article in PDF format. This article was published in error and retracted on February 23, 2024. Please access the updated version here. Effective for dates of service on and after May 1, 2024, the specialty Medicare Part B drugs listed in the table below will be included in our precertification review process.
Federal and state law, as well as state contract language and CMS guidelines (including definitions and specific contract provisions/exclusions), take precedence over these precertification rules and must be considered first when determining coverage. Noncompliance with new requirements may result in denied claims.
HCPCS or CPT® codes
| Medicare Part B drugs
| J3490, J3590, J9999, C9399
| Elrexfio (elranatamab-bcmm)
| J3490, J3590
| Eylea HD (aflibercept)
| J3490, J3590
| Pombiliti (cipaglucosidase alfa-atga)
| J3490, J3590, J9999, C9399
| Talvey (talquetamab-tgvs)
| J3490, J3590
| Tyruko (natalizumab-sztn)
| J3590, C9399
| Veopoz (pozelimab-bbfg)
| J3490
| Ycanth (cantharidin)
|
Anthem Blue Cross and Blue Shield is the trade name of Anthem Health Plans of Maine, Inc. Independent licensee of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MEBCBS-CR-046710-23-CPN45768 Hispanics are the largest ethnic minority group in the United States, making it vital that we recognize the unique health needs of the population. Take time in February to support American Heart Health Month and explore how your practice can help improve your Hispanic patients’ heart health. What can your practice do to help improve health outcomes for Hispanic patients with heart disease?- Be proactive about asking if the patient requires interpretation services. No one wants to feel like a burden. By asking and preparing for an interpreter in advance, you are creating a welcoming atmosphere for the patient during their appointment. If you would like to request an interpreter, including sign language, on behalf of your Anthem Blue Cross and Blue Shield patients, call Provider Services. Free interpreter services are also available to members by calling the Member's Services number on the back of their ID card (TTY/TTD 711) and through the 24/7 NurseLine.
- According to a study by the American Heart Association (link), Hispanic persons had similar rates of heart disease compared to Caucasian adults but lower rates of awareness and control. To help increase awareness of their condition, you can ask questions such as:
- “Have you ever been told that you have high blood pressure or high cholesterol?”
- “Has a healthcare provider ever discussed with you or prescribed you medication to control your blood pressure or cholesterol levels?”
- Once awareness of the condition is properly understood, educate the patient on any increased health risk factors they might have, especially if they have other conditions like diabetes or obesity.
- Use culturally appropriate examples when discussing lifestyle changes. Select here for our conversation guide for tips on how to engage patients who may be from a culture different from your own.
- Encourage scheduling follow-up appointments for blood pressure rechecks or lab work to check cholesterol levels before the patient leaves the office.
- Submit all blood pressure readings using Category II codes on claims or through your practice’s preferred supplemental data submission method. Blood pressure care gaps can open and close through the year and are based on the last recorded blood pressure reading of the year. The goal for every patient is a reading below 140/90 mmHg.
- Properly code statin therapy exclusions and prescribe low-cost medications to discourage the use of discount cards.
To learn more about our commitment to health equity, visit MyDiversePatients.com. Your patients can also learn more about the unique health needs of Hispanic persons by visiting takingactionforourhealth.org/. Patient care opportunitiesIf you have questions on improving your quality scores, contact your care consultant or program manager to discuss your opportunities. You also can find patient care opportunities within the Patient360 application located on Availity Essentials Payer Spaces. To access the Patient360 application you must have the Patient360 role assignment. From Availity’s home page, select Payer Spaces, then choose the health plan from the menu. Choose the Patient360 tile from the Payer Space Applications menu and complete the required information on the screen. Gaps in care are in the Active Alerts section of the Member Summary. What if I need assistance?If you have questions about this communication or need assistance with any other item, contact your local provider relationship management associate or call Provider Services on the back of your patient’s member ID card. Through our efforts, we can help deliver high quality, equitable healthcare. Anthem Blue Cross and Blue Shield is the trade name of Anthem Health Plans of Maine, Inc. Independent licensee of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CM-040702-23-CPN39313 Hispanics are the largest ethnic minority group in the United States, making it vital that we recognize the unique health needs of the population. Take time in February to support American Heart Health Month and explore how your practice can help improve your Hispanic patients’ heart health. What can your practice do to help improve health outcomes for Hispanic patients with heart disease?- Be proactive about asking if the patient requires interpretation services. No one wants to feel like a burden. By asking and preparing for an interpreter in advance, you are creating a welcoming atmosphere for the patient during their appointment. If you would like to request an interpreter, including sign language, on behalf of your AMH Health, LLC patients, call Provider Services. Free interpreter services are also available to members by calling the Member's Services number on the back of their ID card (TTY/TTD 711) and through the 24/7 NurseLine.
- According to a study by the American Heart Association (link), Hispanic persons had similar rates of heart disease compared to Caucasian adults but lower rates of awareness and control. To help increase awareness of their condition, you can ask questions such as:
- “Have you ever been told that you have high blood pressure or high cholesterol?”
- “Has a healthcare provider ever discussed with you or prescribed you medication to control your blood pressure or cholesterol levels?”
- Once awareness of the condition is properly understood, educate the patient on any increased health risk factors they might have, especially if they have other conditions like diabetes or obesity.
- Use culturally appropriate examples when discussing lifestyle changes. Select here for our conversation guide for tips on how to engage patients who may be from a culture different from your own.
- Encourage scheduling follow-up appointments for blood pressure rechecks or lab work to check cholesterol levels before the patient leaves the office.
- Submit all blood pressure readings using Category II codes on claims or through your practice’s preferred supplemental data submission method. Blood pressure care gaps can open and close through the year and are based on the last recorded blood pressure reading of the year. The goal for every patient is a reading below 140/90 mmHg.
- Properly code statin therapy exclusions and prescribe low-cost medications to discourage the use of discount cards.
To learn more about our commitment to health equity, visit MyDiversePatients.com. Your patients can also learn more about the unique health needs of Hispanic persons by visiting takingactionforourhealth.org/. Patient care opportunitiesIf you have questions on improving your quality scores, contact your care consultant or program manager to discuss your opportunities. You also can find patient care opportunities within the Patient360 application located on Availity Essentials Payer Spaces. To access the Patient360 application you must have the Patient360 role assignment. From Availity’s home page, select Payer Spaces, then choose the health plan from the menu. Choose the Patient360 tile from the Payer Space Applications menu and complete the required information on the screen. Gaps in care are in the Active Alerts section of the Member Summary. What if I need assistance?If you have questions about this communication or need assistance with any other item, contact your local provider relationship management associate or call Provider Services on the back of your patient’s member ID card. Through our efforts, we can help deliver high quality, equitable healthcare. MEAMH-CR-040691-23-CPN39313 |